REFERENCES
- McKinnon SJ, Lehman DM, Kerrigan-Baumrind LA, et al. Caspase activation and amyloid precursor protein cleavage in rat ocular hypertension. Invest Ophthalmol Vis Sci. 2002; 43:1077–1087.
- Moya KL, Benowitz LI, Schneider GE, et al. The amyloid precursor protein is developmentally regulated and correlated with synaptogenesis. Dev Biol. 1994;16:597–603.
- Masliah E. Mechanisms of synaptic dysfunction in Alzheimer’s disease. Histol Histopathol. 1995;10:509–519.
- Morin PJ, Abraham CR, Amaratunga A, et al. Amyloid precursor protein is synthesized by retinal ganglion cells, rapidly transported to the optic nerve plasma membrane and nerve terminals, and metabolized. J Neurochem. 1993;6:464–473.
- Bayer AU, Ferrari F, Erb C. High occurrence rate of glaucoma among patients with Alzheimer’s disease. Eur Neurol. 2002;47:165–168.
- Wostyn P, Audenaert K, De Deyn PP. Alzheimer’s disease-related changes in diseases characterized by elevation of intracranial or intraocular pressure. J Neurochem. 1993;61:464–473.
- Goldblum D, Kipfer-Kauer A, Sarra GM, et al. Distribution of amyloid precursor protein and amyloid-beta immunoreactivity in DBA/2J glaucomatous mouse retinas. Invest Ophthalmol Vis Sci. 2007;48:5085–5090.
- McKinnon SJ, Reitsamer HA, Ransom NL, et al. Induction and tonopen measurement of ocular hypertension in C57BL/6 mice. Invest Ophthalmol Vis Sci. 2003;44:e-abstract 3319.
- Morrison JC, Moore CG, Deppmeier LM, et al. A rat model of chronic pressure-induced optic nerve damage. Exp Eye Res. 1997;64:85–96.
- Sturchler-Pierrat C, Abramowski D, Duke M, et al. Two amyloid precursor protein transgenic mouse models with Alzheimer disease-like pathology. Proc Natl Acad Sci U S A. 1997;94:13287–13292.
- Schrader-Fischer G, Paganetti PA. Effect of alkalizing agents on the processing of the beta-amyloid precursor protein. Brain Res. 1996;716:91–100.
- Meyer-Luehmann M, Coomaraswamy J, Bolmont T, et al. Exogenous induction of cerebral beta-amyloidogenesis is governed by agent and host. Science. 2006;313:1781–1784.
- Janciauskiene S, Krakau T. Alzheimer’s peptide and serine proteinase inhibitors in glaucoma and exfoliation syndrome. Doc Ophthalmol. 2003;106:215–223.
- Walsh MM, Yi H, Friedman J, et al. Gene and protein expression pilot profiling and biomarkers in an experimental mouse model of hypertensive glaucoma. Exp Biol Med. 2009;234:918–930.
- McKinnon SJ. Glaucoma: Ocular Alzheimer’s disease? Front Biosci. 2003;8:1140–1156.
- Martin KR, Quigley HA, Valenta D, et al. Optic nerve dynein motor protein distribution changes with intraocular pressure elevation in a rat model of glaucoma. Exp Eye Res. 2006;83:255–262.
- Kamal A, Almenar-Queralt A, LeBlanc JF, et al. Kinesin-mediated axonal transport of a membrane compartment containing beta-secretase and presenilin-1 requires APP. Nature 2001;414:643–648.
- Yankner BA, Duffy LK, Kirschner DA. Neurotrophic and neurotoxic effects of amyloid beta protein: Reversal by tachykinin neuropeptides. Science. 1990;250:279–282.
- Guo L, Salt TE, Luong V, et al. Targeting amyloid-beta in glaucoma treatment. Proc Natl Acad Sci U S A. 2007;104:13444–13449.
- Santiago-García J, Mas-Oliva J, Innerarity TL, et al. Secreted forms of the amyloid-beta precursor protein are ligands for the class A scavenger receptor. J Biol Chem. 2001;276:30655–30661.
- Joachim CL, Duffy LK, Morris JH, et al. Protein chemical and immunocytochemical studies of meningovascular beta-amyloid protein in Alzheimer’s disease and normal aging. Brain Res. 1988;474:100–111.
- Kim DH, Kim HS, Ahn MD, et al. Ganglion cell death in rat retina by persistent intraocular pressure elevation. Korean J Ophthalmol. 2004;18:15–22.
- Guo L, Moss SE, Alexander RA, et al. Retinal ganglion cell apoptosis in glaucoma is related to intraocular pressure and IOP-induced effects on extracellular matrix. Invest Ophthalmol Vis Sci. 2005;46:175–182.
- Dovey HF, John V, Anderson JP, et al. Functional gamma-secretase inhibitors reduce beta-amyloid peptide levels in brain. J Neurochem. 2001;76:173–181.
- McKinnon SJ, Lehman DM, Tahzib NG, et al. Baculoviral IAP repeat-containing-4 protects optic nerve axons in a rat glaucoma model. Mol Ther. 2002;5:780–787.
- Bard F, Cannon C, Barbour R, et al. Peripherally administered antibodies against amyloid beta-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease. Nat Med. 2000;6:916–919.
- Wilcock DM, Jantzen PT, Li Q, et al. Amyloid-beta vaccination, but not nitro-nonsteroidal anti-inflammatory drug treatment, increases vascular amyloid and microhemorrhage while both reduce parenchymal amyloid. Neuroscience. 2007;144:950–960.